shanxi
provinc
china
sar
epicent
outbreak
studi
serum
sampl
taken
patient
design
sar
hospit
provinc
followup
serum
sampl
taken
month
year
onset
symptom
total
case
met
world
health
organ
sar
case
definit
known
transmiss
histori
includ
studi
studi
conduct
part
nation
sar
control
prevent
program
use
serum
human
particip
approv
committe
sar
control
prevent
depart
scienc
technolog
peopl
republ
china
titer
serum
antibodi
sarscov
determin
use
commerci
avail
elisa
kit
bjigbi
biotechnolog
beij
china
elisa
base
inactiv
prepar
wholeviru
lysat
kit
first
commerci
kit
approv
chines
food
drug
administr
specif
detect
sarscov
antibodi
wide
use
sever
studi
manufactur
instruct
follow
without
modif
briefli
everi
elisa
plate
blank
posit
neg
control
includ
detect
immunoglobulin
g
igg
dilut
test
serum
ad
antigenco
well
plate
incub
min
horseradish
peroxid
hrp
antihuman
igg
ad
detect
bound
antibodi
detect
igm
incub
primari
antibodi
extend
min
follow
detect
hrpconjug
antihuman
igm
optic
densiti
od
read
deem
valid
neg
control
od
posit
control
elisa
plate
cutoff
igg
igm
determin
defin
respect
plu
od
neg
control
od
neg
control
use
calcul
studi
od
read
neg
control
differ
test
consist
cutoff
od
igg
igm
respect
serum
sampl
od
greater
equal
cutoff
valu
consid
posit
weak
posit
sampl
ie
od
cutoff
valu
retest
duplic
day
reproduc
posit
result
includ
final
analysi
data
process
use
excel
version
microsoft
corp
redmond
wa
usa
spss
softwar
version
window
spss
inc
chicago
il
usa
among
cohort
p
igg
posit
indic
patient
met
case
definit
inde
infect
sarscov
shown
tabl
day
onset
symptom
percentag
igg
posit
percentag
continu
increas
reach
day
remain
larg
unchang
day
furthermor
year
patient
respect
igg
posit
suggest
immun
respons
maintain
patient
year
howev
year
later
convalesc
popul
igg
od
chang
correl
chang
iggposit
percentag
although
rate
chang
vari
od
read
posit
percentag
peak
day
howev
rate
reduct
averag
od
read
much
faster
drop
year
respect
symptom
onset
figur
similar
observ
obtain
igm
trend
cohort
percentag
patient
igm
posit
within
first
day
peak
day
tabl
pattern
igmposit
percentag
averag
od
read
similar
peak
day
day
averag
od
read
drop
close
cutoff
valu
among
cohort
patient
known
transmiss
histori
abl
obtain
complet
collect
serum
sampl
patient
month
year
igg
level
patient
analyz
separ
obtain
igg
trend
accur
repres
convalesc
sar
patient
figur
patient
posit
igg
month
year
ie
posit
patient
becam
igg
neg
year
howev
year
posit
percentag
drop
reduct
od
valu
mimick
posit
percentag
faster
rate
averag
od
read
drop
month
year
repres
reduct
od
drop
reduct
year
year
knowledg
followup
conduct
studi
longest
longitudin
studi
ever
report
larg
number
patient
confirm
transmiss
histori
complet
dataset
level
confid
high
result
obtain
studi
repres
convalesc
sar
patient
similar
result
report
longitudin
studi
sar
patient
smaller
cohort
size
patient
shorter
followup
period
day
year
gener
trend
igm
peak
month
symptom
onset
igg
peak
month
consist
among
differ
studi
result
provid
strong
evid
sarscov
antibodi
reduc
year
symptom
onset
antibodi
play
import
role
protect
immun
sarscov
find
studi
import
implic
regard
assess
risk
reinfect
among
previous
expos
popul
eg
hospit
staff
evalu
durat
antibodymedi
immun
candid
vaccin
could
provid
